[利拉鲁肽、西他列汀/二甲双胍、利格列汀和西他列汀治疗后的糖尿病指标]

[Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin].

作者信息

Atonal-Flores Beatriz, León-Vázquez María de la Luz, Barranco-Juarez Armando

机构信息

Instituto Mexicano del Seguro Social. Unidad de Medicina Familiar No. 7, Servicio de Epidemiología. Zacatelco, Tlaxcala, México.

Instituto Mexicano del Seguro Social, Coordinación de Planeación y Enlace Institucional, Servicio Coordinación de Investigación. Tlaxcala, Tlaxcala, México.

出版信息

Rev Med Inst Mex Seguro Soc. 2023 Jul 31;61(4):489-495. doi: 10.5281/zenodo.8200442.

DOI:10.5281/zenodo.8200442

PMID:37540652

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10484544/

Abstract

BACKGROUND

The control of diabetes mellitus is multifactorial, the different therapeutic options make it necessary to compare the effectiveness with previous therapeutic schemes.

OBJECTIVE

Analize the indicators of control of diabetes mellitus after incorporating liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin.

METHODS

Observational, analytical, longitudinal study. Glucose, glycosylated hemoglobin, and blood pressure were compared after the inclusion of new cues in patients with diabetes mellitus; in addition to the control indicators reported in the unit in october, november, and december 2000, with those of 2021 in the same months. A descriptive analysis was performed, T for related samples and McNemar, a value of < .05 was considered significant, a confidence level of 95%, with the IBM-SPSS 24 software.

RESULTS

352 files were analyzed, 59% women, aged 26 to 88 years, and the percentage of control decreased after the change of scheme (38.4% vs 35.8%) without a statistical difference (p .503). There was no statistical difference between the levels of glucose, glycated hemoglobin, weight, and blood pressure before and six months after the change. In the unit, the regimen glycemic control indicator improved in October, November, and December 2020 compared to the same months in 2021, it increased (from 17.2, 18.7, and 16.3, to 41.6, 47.2, and 46.5%). Blood pressure control went from 64.5, 66.7, and 67 to 82.4, 85.1, and 83.1%.

CONCLUSIONS

The control indicators in the unit improved, however, the patients who used the new keys did not show any difference.

摘要

背景

糖尿病的控制是多因素的，不同的治疗选择使得有必要将其有效性与先前的治疗方案进行比较。

目的

分析纳入利拉鲁肽、西格列汀/二甲双胍、利格列汀和西格列汀后糖尿病的控制指标。

方法

观察性、分析性纵向研究。比较糖尿病患者纳入新药物后的血糖、糖化血红蛋白和血压；除了2000年10月、11月和12月该科室报告的控制指标外，还与2021年相同月份的指标进行比较。使用IBM-SPSS 24软件进行描述性分析、相关样本T检验和McNemar检验，P值<0.05被认为具有统计学意义，置信水平为95%。

结果

分析了352份病历，女性占59%，年龄在26至88岁之间，方案改变后控制率有所下降（38.4%对35.8%），但无统计学差异（P=0.503）。方案改变前和改变后六个月的血糖、糖化血红蛋白、体重和血压水平之间无统计学差异。在该科室，2020年10月、11月和12月的血糖控制指标与2021年相同月份相比有所改善，呈上升趋势（从17.2%、18.7%和16.3%升至41.6%、47.2%和46.5%）。血压控制率从64.5%、66.7%和67%升至82.4%、85.1%和83.1%。